2015 Annual Meeting | 7MS.001 - Differential Diagnosis of Dementia: Linking Clinical Syndromes to Biomarkers

Date Friday 04/24/15

Time 06:30 AM - 08:00 AM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Morning Seminar

Director(s) Jeffrey M. Burns, MD

Topic(s)

Learning Objectives Participants should understand the basis for the clinical diagnoses of Alzheimer's disease in relation to dementing disorders that often mimic its presentation and should also understand the potential clinical utlility of biofluid and imaging biomarkers for Alzheimer's disease.

CME Available 1.50 CME credits

Core Competencies Patient Care & Procedural Skills, Medical Knowledge

Recommended Audience Trainee, General Neurologist, Non-neurologist

Teaching Styles Case-based, Didactic, Audience Participation

Event Timeline
06:30 AM - 06:45 AM		Alzheimer's Biomarkers Jeffrey M. Burns, MD
06:45 AM - 08:00 AM		Case Studies Jeffrey M. Burns, MD, Howard J. Rosen, MD

Faculty Disclosures
Jeffrey M. Burns, MD	Dr. Burns has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Renew Research. Dr. Burns has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Burns has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amylyx. Dr. Burns has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Norris, Keplinger, Hicks and Welder. The institution of Dr. Burns has received research support from National Institutes of Health. The institution of Dr. Burns has received research support from Biogen. The institution of Dr. Burns has received research support from Eli Lilly. The institution of Dr. Burns has received research support from Amylyx. The institution of Dr. Burns has received research support from Abbvie. The institution of Dr. Burns has received research support from Astra-Zeneca.
Howard J. Rosen, MD	Dr. Rosen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai Pharmaceuticals. Dr. Rosen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. The institution of Dr. Rosen has received research support from NIH. The institution of Dr. Rosen has received research support from State of CA. Dr. Rosen has a non-compensated relationship as a Consultant with Alector that is relevant to AAN interests or activities. Dr. Rosen has a non-compensated relationship as a Consultant with Prevail Therapeutics that is relevant to AAN interests or activities. Dr. Rosen has a non-compensated relationship as a consultant with Alchemab that is relevant to AAN interests or activities.

��ɫ��

��ɫ��